3 Mar 03
20030101961

162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22607 A1

(51) International Patent Classification[7]: C07D 403/12, 401/14, A61K 31/506, 31/4155, A61P 35/00, C07D 403/14, 405/14, 409/14, 471/04, 487/04, 401/12, 493/04, 498/04, 513/04

(21) International Application Number: PCT/US01/28940

(22) International Filing Date:
14 September 2001 (14.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/232,795	15 September 2000 (15.09.2000)	US
60/257,887	21 December 2000 (21.12.2000)	US
60/286,949	27 April 2001 (27.04.2001)	US

(71) Applicant *(for all designated States except US)*: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; Patent Department, 130 Waverly Street, Cambridge, MA 02139-4242 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAVIES, Robert** [US/US]; 65 Orient Avenue, Arlington, MA 02474 (US). **BEBBINGTON, David** [GB/GB]; 6 Linden Close, Newbury, Berkshire R6141QA (GB). **KNEGTEL, Ronald** [GB/GB]; 3 Bath Court, Bath Street, Abingdom, Bath and South East Somerset OX1X1EE (GB). **WANNAMAKER, Marion** [US/US]; 375 Harvard Road, Stow, MA 01775 (US). **LI, Pan** [CN/US]; 15 Mystic View Terrace, Arlington, MA 02474 (US). **FORESTER, Cornelia** [US/US]; 8 Nancy Avenue, Pelham, NH 03076 (US). **PIERCE, Albert** [US/US]; 123 Orchard Street, Apartment 36, Somerville, MA 02144 (US). **KAY, David** [GB/GB]; 4 Church Path, Purton, Purton, Wiltshire 02144 (GB).

(74) Agents: **SILVERMAN, Ian** et al.; Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, MA 02139-4242 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *entirely in electronic form (except for this front page) and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ACTION

WO 02/22607 A1

(54) Title: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

(57) Abstract: This invention describes novel pyrazole compounds of formula II:wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2, 4-triazinyl ring, and R^2, R^2, R^x, and R^y are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R^2 and R^2 are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and R^x and R^y are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.